Taking vitamin K along with usual treatment for liver cancer does not help patients live longer. The numbers show no clear improvement in survival from adding vitamin K.
See the scientific wording
Vitamin K supplementation, when added to standard therapy, does not significantly improve overall survival in patients with hepatocellular carcinoma, based on a pooled hazard ratio of 0.77 (95% CI 0.58–1.01), indicating no survival benefit from this adjunctive treatment.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
The study looked at liver cancer patients and found that taking vitamin K didn't clearly help them live longer, which matches the claim that it doesn't improve survival.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K stops liver cancer cells from dividing and prevents the tumor from growing new blood vessels. These effects slow the tumor, but patients still die from their cancer because the tumor continues to damage the liver.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking vitamin K along with usual treatment for liver cancer does not help patients live longer. The numbers show no clear improvement in survival from adding vitamin K.
Mechanism
1 studyVitamin K acts on liver cancer cells in two ways: it stops them from dividing and it blocks the growth of new blood vessels that feed the tumor. Even though these actions slow the cancer down, they do not help patients live longer because the cancer continues to harm the liver and eventually causes death.
Vitamin K stops liver cancer cells from dividing and prevents the tumor from growing new blood vessels. These effects slow the tumor, but patients still die from their cancer because the tumor continues to damage the liver.
Vitamin K inhibits the kinase activity of IKK.
Inhibition of IKK prevents IκB phosphorylation, thereby stabilizing the NF-κB complex in an inactive state.
Inactive NF-κB reduces the expression of cyclin D1 and HCC-derived growth factor, slowing cell cycle progression.
Vitamin K also inhibits PKC and PKD1, which further suppresses NF-κB and activates the protein kinase A/p53 pathway.
Activation of p53 promotes p21 transcription, leading to cell cycle arrest.
Vitamin K selectively inhibits VEGFR2 phosphorylation.
Inhibition of VEGFR2 phosphorylation blocks downstream angiogenic signaling, preventing new blood vessel formation.
Evidence from Studies
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
The study looked at liver cancer patients and found that taking vitamin K didn't clearly help them live longer, which matches the claim that it doesn't improve survival.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials of Vitamin K as Adjunct Therapy for Hepatocellular Carcinoma
Conduct a comprehensive search of multiple databases for RCTs comparing vitamin K plus standard therapy versus placebo plus standard therapy in adults with hepatocellular carcinoma, with overall survival as the primary outcome. Follow-up of at least 12 months, with meta-analysis of hazard ratios using random-effects models.
Double-Blind Randomized Controlled Trial of Vitamin K vs. Placebo as Add-On to Standard Care for Unresectable Hepatocellular Carcinoma
Randomize patients with newly diagnosed, unresectable hepatocellular carcinoma to receive either vitamin K (at a therapeutic dose) or placebo in addition to standard therapy (e.g., sorafenib or chemoembolization). Stratify by tumor stage and liver function. Primary outcome: overall survival, with intention-to-treat analysis and a follow-up of at least 24 months.
Prospective Cohort Study of Vitamin K Supplementation and Survival in Patients with Hepatocellular Carcinoma
Enroll a cohort of adults diagnosed with hepatocellular carcinoma, documenting vitamin K use (supplementation type, dose, duration) and standard treatment received. Follow them prospectively for at least 5 years, measuring overall survival. Use multivariable Cox regression to adjust for known prognostic factors (e.g., tumor stage, liver function, comorbidities).
Retrospective Case-Control Study of Vitamin K Exposure and Survival in Hepatocellular Carcinoma Patients
Identify deceased HCC patients (cases) and living HCC patients (controls) matched by age, sex, tumor stage, and treatment. Use medical records or interviews to determine vitamin K supplement use before and during treatment. Compare odds of survival to assess association.